Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 3/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123143 | 0.78 | POLB (0.41) | POLBHRH3LTA4HPIM1PIM2 | |
| SCHEMBL2124369 | 0.76 | POLB (0.47) | POLBHRH3LTA4HPIM1PIM2 | |
| SCHEMBL2616550 | 0.75 | LTA4H (0.38) | POLBLTA4HCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL312572 | 0.73 | PDE8B (0.41) | POLBHRH3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2120243 | 0.73 | LTA4H (0.41) | POLBLTA4H | |
| Ammonia Solution, Strong SCHEMBL312538 | 0.72 | PDE8B (0.40) | POLBHRH3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2120480 | 0.71 | LTA4H (0.41) | POLBHRH3LTA4HPIM1PIM2 | |
| SCHEMBL7796172 | 0.70 | ALDH1A1 (0.42) | POLBHRH3PIM1PIM2CYP1A2 | |
| SCHEMBL2123153 | 0.68 | POLB (0.47) | POLBHRH3LTA4HPIM1PIM2 | |
| SCHEMBL2514924 | 0.68 | POLB (0.43) | POLBHRH3PIM1PIM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093255-B2 | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093255-B2 | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093255-B2 | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100160344-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160344-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160344-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160344-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ENTPD5 | POLB 2354/4885HRH3 920/4885LTA4H 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.